Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Napolitano Andrea, Joensuu Heikki, Rothschild Sara, Evans Denisse, Heinrich Michael C, Sutton Thomas L, Mayo Skye C, Boye Kjetil, Falkenhorst Johanna, Le Cesne Axel, Hohenberger Peter, Rutkowski Piotr, van Houdt Winan J, Steeghs Neeltje, Gelderblom Hans, Desar Ingrid M E, Pantaleo Maria A, Nishida Toshiro, Reichardt Peter, Blay Jean-Yves, Somaiah Neeta, Haddad Elise F Nassif, Grignani Giovanni, Baldi Giacomo G, Steigen Sonja E, Braconi Chiara, Nilsson Bengt, Singh Arun S, Fumagalli Elena, Cananzi Ferdinando C M, Italiano Antoine, Ceruso Mariella Spalato, Brunello Antonella, Magnússon Magnús K, Jonasson Jon G, Marquina Gloria, Hindi Nadia, Cirilli Claudia, Federico Massimo, Fausti Valentina, Bordoni Andrea, Sufliarsky Jozef, Mazzocca Alessandro, Martin-Broto Javier, Gronchi Alessandro, Trent Jonathan C, Casali Paolo G, Bauer Sebastian, Jones Robin L, Vincenzi Bruno
Аннотация
OBJECTIVE: To evaluate the association between adjuvant imatinib and recurrence-free survival (RFS) and overall survival (OS) in patients with resected GISTs with KIT exon 9 mutations.
DESIGN, SETTING, AND PARTICIPANTS: This international, multicenter cohort study included patients with localized, molecularly confirmed GISTs with KIT exon 9 mutations who underwent curative-intent surgery between January 1990 and July 2022 at 35 referral centers in Europe, the US, and Japan, or were registered in the Life Raft Group database. The analysis took place between January 2025 and November 2025.
EXPOSURES: Adjuvant imatinib initiated after curative surgery, modeled as a time-dependent covariate to account for immortal time bias.
MAIN OUTCOMES AND MEASURES: The primary end points were RFS (time from surgery to recurrence or death) and OS (time from surgery to death) in the full cohort and in the high-risk subgroup defined by modified National Institutes of Health (mNIH) criteria. Multivariable Cox regression models included established prognostic covariates and cluster-robust standard errors. Overlap weighting (OW) based on propensity scores was used as a causal inference model. Secondary analyses evaluated 400 mg/d vs 800 mg/d dosing in the mNIH high-risk subgroup.
RESULTS: A total of 367 patients were included, 187 (51.0%) male and 180 (49%) female, with a mean (SD) age of 56 (13) years. Among these, 91 (24.8%) were observed and 276 (75.2%) received adjuvant imatinib (median [IQR] duration, 27.3 [13.5-36.0] months; 116 [42.0%] treated ≥3 years). Consistent with a cytostatic activity, adjuvant imatinib in the full cohort was associated with a reduced early hazard of recurrence or death (HR, 0.19; 95% CI, 0.10-0.36), with attenuation over time (time-interaction hazard ratio [HR], 1.85 per log-year). Treatment was also associated with improved OS (HR, 0.37; 95% CI, 0.17-0.83). Similar results were obtained when limiting the analysis to patients with mNIH high-risk disease. OW models and sensitivity analyses confirmed similar associations with RFS and OS. Among 257 patients with mNIH high-risk disease receiving imatinib, no significant difference was observed between 400 mg/d and 800 mg/d dosing.
CONCLUSION AND RELEVANCE: In this large international cohort study of resected GISTs with KIT exon 9 mutations, adjuvant imatinib was independently associated with delayed recurrence and improved survival. These findings support the use of adjuvant imatinib in mNIH high-risk GISTs with KIT exon 9 mutations and underscore the need for prospective studies to define optimal dosing and treatment duration.